Clinical trials: High Risk Neuroblastoma
Neuroblastoma, Neuroblastoma Recurrent
Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors
The purpose of this study is to test the safety and efficacy of GD2-CART01, a CAR T cell treatment targeting GD2 in paediatric or young adult patients with High Risk and/or relapsed/refractory Neuroblastoma.
- Conditions
- Neuroblastoma, Neuroblastoma Recurrent, GD2-positive Solid Tumors, Osteosarcoma
- Trial name
- NCT03373097
- Testing
- GD2-CART01
- Where
- Italy
- Volunteers
- 42 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Cancer
Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients
RATIONALE: Liposomal amphotericin B may be effective in controlling fever and granulocytopenia. It is not yet known which regimen of liposomal amphotericin B is more effective in treating cancer patients who have these…
- Trial name
- NCT00003938
- Testing
- liposomal amphotericin B
- Where
- 24 sites in Belgium, Czechia and 13 more
- Volunteers
- 115 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Neuroblastoma
A Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta
This is a non-interventional, multi-national, observational, prospective patient registry to further evaluate the effectiveness and safety of dinutuximab beta - a monoclonal immunoglobulin G 1 (IgG1) antibody, to obtain…
- Trial name
- NCT04253015
- Testing
- Data-collection
- Where
- 13 sites in Austria, France and 5 more
- Volunteers
- 125 people
- Sponsor
- RECORDATI GROUP
Neuroblastoma
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
This is a standard of care document, outlining the therapy for children with high risk neuroblastoma who are not eligible for Children's Oncology Group (COG) studies.
- Trial name
- NCT01526603
- Testing
- Carboplatin, Autologous stem cell infusion, Granulocyte colony stimulating factor
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Newly Diagnosed High Risk Neuroblastoma
Response-based Treatment of High-risk Neuroblastoma
The purpose of this study is to improve outcome of high risk neuroblastoma by tailoring the treatment intensity of tandem high dose chemotherapy according to the treatment response to induction chemotherapy.
- Trial name
- NCT02771743
- Testing
- Cisplatin, Doxorubicin, Etoposide
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Samsung Medical Center
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Adult Central Nervous System Germ Cell Tumor
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them.
- Conditions
- Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor
- Trial name
- NCT00638898
- Testing
- busulfan, melphalan, topotecan hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Recurrent Neuroblastoma, Stage 2A Neuroblastoma
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
This research trial studies late effects after treatment in patients with previously diagnosed high-risk neuroblastoma. Studying late effects after treatment may help to decide which treatments for high-risk neuroblastoma are…
- Conditions
- Recurrent Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma
- Trial name
- NCT03057626
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 98 sites in United States, Australia and 2 more
- Volunteers
- 376 people
- Sponsor
- Children's Oncology Group
Recurrent Neuroblastoma
Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma
This phase II trial is studying how well fenretinide works in treating children with recurrent or resistant neuroblastoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or…
- Trial name
- NCT00053326
- Testing
- fenretinide, pharmacological study
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.
RATIONALE: - Relapsed or refractory Neuroblastoma (NBL) carries a very poor prognosis and children with relapsed NBL have an overall 3 year survival rate of < 10%.
- Trial name
- NCT00874315
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- 4 sites in United States
- Sponsor
- Nationwide Children's Hospital
Neuroblastoma
GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.
This exploratory clinical study will evaluate the efficacy and feasibility of combining a GSL synthase inhibitor with a granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with advanced or metastatic…
- Trial name
- NCT07090538
- Testing
- Eliglustat
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Chinese PLA General Hospital
Head and Neck Cancer
Head & Neck Cancer Survivorship: Physical and Functional Status
RATIONALE: Early physical therapy may be effective in improving range of motion of the neck and shoulders in head and neck cancer survivors who are undergoing chemotherapy and radiation therapy.
- Trial name
- NCT00751816
- Testing
- systemic chemotherapy, survey administration, adjuvant therapy
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Vanderbilt University
Relapsed Neuroblastoma, Refractory Neuroblastoma
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
This illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neuroblastoma.
- Conditions
- Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma, Ganglioneuroblastoma
- Trial name
- DUAL-NK-NB (NCT07502287)
- Testing
- EB-DTNB-NK, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
CNS Embryonal Tumor, CNS, Medulloblastoma
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
Pilot study to determine feasibility of adding intrathecal chemotherapy and maintenance therapy after high dose chemotherapy for treatment of newly diagnosed HR-EBTs in patients less than 6 years of age.
- Conditions
- CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor, Medulloblastoma, Childhood
- Trial name
- NCT06942039
- Testing
- Cytarabine IT, hydrocortisone, Cisplatin
- Where
- 12 sites in Canada
- Volunteers
- 15 people
- Sponsor
- C17 Council